13 In a safety analysis, TEAEs included diarrhea (48.8%), nausea (29.5% ... Data accumulated to date with respect to various PI3K inhibitors suggest improved response rates and longer survival ...

Infinity Pharmaceuticals has gained access to Intellikine's portfolio of phosphoinositide 3-kinase-δ (PI3Kδ) and PI3Kγ inhibitors for inflammation and oncology indications through an exclusive ...

The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi ... and creatinine; and stomatitis; diarrhea; fatigue; rash; ...